At two years, at least 70% of patients on Johnson & Johnson’s psoriasis pill had clear or almost clear skin.

Johnson & Johnson (JNJ) reported two-year results from its Phase 3 ICONIC-LEAD study of ICOTYDE for plaque psoriasis, showing sustained skin clearance and symptom improvements. At Week 112, 72% of patients achieved PASI 90, 70% had clear/almost clear skin, and 44% had complete clearance. Safety findings were consistent with the drug's profile. JNJ is also studying ICOTYDE for other conditions. JNJ closed at $256.48, down 0.76%, and was down 0.15% in premarket trading.

Johnson & Johnson (JNJ) presented two-year Phase 3 data for ICOTYDE® (icotrokinra) at Fall Clinical Dermatology 2026, showing sustained skin clearance and safety in treating plaque psoriasis. 72% of patients achieved PASI 90, and 70% achieved IGA 0/1. The drug is approved for adults and adolescents with moderate-to-severe plaque psoriasis.

Johnson & Johnson (JNJ) reported positive two-year Phase 3 trial results for ICOTYDE, an oral peptide for plaque psoriasis, with 72% of patients achieving significant skin improvement. The company offers a 1.98% dividend yield, a 55% payout ratio, and a 4.9% 3-year dividend growth rate, but its stock is 32% overvalued relative to its GF Value. JNJ has a GF Score of 83/100, indicating strong financial health and profitability, though insider activity shows significant net selling.

Johnson & Johnson reported two-year data from the ICONIC-LEAD study, showing high skin clearance and symptom improvement with ICOTYDE in plaque psoriasis patients. No new safety issues were found. According to the company, ICOTYDE is a significant advancement in treatment. JNJ shares are down 0.10% in pre-market trading.

Johnson & Johnson (JNJ) presented two-year data from its Phase 3 ICONIC-LEAD study of Icotyde for psoriasis, showing sustained skin clearance and safety. The drug is approved in the U.S., Europe, Japan, and China. JNJ shares rose 15% premarket. Icotyde is also being studied for other conditions.

Johnson & Johnson (JNJ) presented two-year Phase 3 data for ICOTYDE® (icotrokinra) at Fall Clinical Dermatology 2026. The study showed high, sustained response rates in adults and adolescents with plaque psoriasis, with 72% achieving clear or almost clear skin and a favorable safety profile. ICOTYDE is the first targeted oral peptide blocking the IL-23 receptor. The company highlights its potential as a first-line systemic therapy.